GPRC5D FcRH5 Bispecific T-Cell Engagers — PatSnap Eureka
GPRC5D & FcRH5 Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma
Antigen escape from BCMA-targeting therapies is driving urgent demand for validated non-BCMA targets. GPRC5D and FcRH5 have emerged as clinically tractable alternatives — with 91% ORR signals in GPRC5D CAR-T and Phase I FcRH5 ADC data — even in daratumumab-refractory populations.
Anti-GPRC5D CAR-T: 91% ORR in Phase II
33 patients, 2×10⁶ cells/kg, 5.2-month median follow-up (Jiangsu Key Lab, 2023)
Four Distinct Approaches Targeting GPRC5D and FcRH5 in RRMM
Retrieved patent and literature signals cover bispecific T-cell engagers, antibody-drug conjugates, CAR-T cell therapy, and multispecific antibody formats — each addressing different aspects of the RRMM treatment challenge.
GPRC5D×CD3 Bispecific: Talquetamab
A peer-reviewed paper from the Institute of Cancer Research, London, reports that talquetamab effectively kills GPRC5D+ myeloma cell lines and bone marrow samples from 45 RRMM patients in the presence of T cells from both healthy donors and heavily pre-treated MM patients. No difference in myeloma cell killing was observed across daratumumab-naïve and daratumumab-refractory samples.
Activity preserved post-anti-CD38 therapyFcRH5-Targeting ADC: DFRF4539A
A Genentech-authored phase I study enrolled 39 RRMM patients receiving DFRF4539A — an anti-FcRH5 antibody conjugated to MMAE — at doses of 0.3–2.4 mg/kg every 3 weeks or 0.8–1.1 mg/kg weekly. Dose-linear pharmacokinetics were confirmed. 37/39 patients (95%) experienced adverse events; 39% experienced grade ≥3 AEs including anemia (26%).
Dose-linear PK confirmedAnti-GPRC5D CAR-T Cell Therapy
A single-arm Phase II trial from Jiangsu Key Laboratory of Bone Marrow Stem Cells reports an overall response rate of 91% (95% CI provided) in 33 RRMM patients infused with anti-GPRC5D CAR-T cells at 2×10⁶ cells/kg after lymphodepletion, with a median follow-up of 5.2 months. This represents one of the most robust clinical signals for GPRC5D as a myeloma target in the dataset.
91% ORR · 33 patients · Phase IIBCMA/GPRC5D/CD3 Trispecific Antibody
A patent filing from Janssen Pharmaceutica N.V. (Israel, 2023) describes multispecific antibodies binding BCMA, GPRC5D, and CD3 simultaneously — designed to address antigen heterogeneity and escape by co-targeting two plasma cell surface antigens while engaging T cells through a single molecular entity.
Intrinsic dual-antigen escape preventionWhy GPRC5D and FcRH5 Are Compelling Beyond BCMA
GPRC5D is an orphan receptor with significantly elevated expression on myeloma plasma cells relative to normal plasma cells and other immune cells. Preclinical data from the Institute of Cancer Research, London, confirm that GPRC5D surface expression is maintained regardless of prior daratumumab exposure or cytogenetic risk profile — making it actionable across diverse patient subpopulations, including daratumumab-refractory cases with a median of six prior therapies. Per WIPO patent databases, IP activity around GPRC5D has intensified markedly since 2020.
FcRH5 (Fc receptor-like 5; encoded by FCRL5) is selectively enriched on malignant plasma cells compared with other hematologic lineages and normal tissues. A Genentech-authored phase I study in this dataset describes FcRH5 as exhibiting this plasma cell-enriched expression pattern, supporting its use as a myeloma-specific target for antibody-based therapeutics. ClinicalTrials.gov records early-phase FcRH5×CD3 TCE (cevostamab) studies showing promising results in RRMM.
A University of Calgary study (2023) systematically examined resistance mechanisms to both BCMA- and GPRC5D-targeting TCE/CAR-T approaches in 30 patients, identifying biallelic deletions at the TNFRSF17 locus (BCMA gene), selective expansion of BCMA-negative subclones, and GPRC5D protein downregulation as tumor-intrinsic escape mechanisms — using combined bulk and single-cell whole-genome sequencing. This provides the primary mechanistic justification for multi-antigen approaches. According to NIH research programs, antigen escape remains the central unresolved challenge in myeloma immunotherapy.
Clinical and Patent Evidence at a Glance
Key quantitative signals from retrieved patent and literature records covering GPRC5D and FcRH5 therapeutic development in RRMM.
GPRC5D CAR-T Phase II: Dose & Response Profile
91% ORR in 33 RRMM patients at 2×10⁶ cells/kg after lymphodepletion; 5.2-month median follow-up (Jiangsu Key Lab, 2023).
FcRH5 ADC (DFRF4539A) Phase I Safety Profile
39 RRMM patients enrolled; 95% experienced any AE, 39% grade ≥3 AEs, 26% anemia (Genentech, 2019).
Commercial Patent Activity: Janssen Dominates, FcRH5 Shows White Space
Innovation in this dataset is driven by a combination of Janssen commercial patent activity and academic literature from multiple international centers. FcRH5 remains under-represented in patent filings relative to GPRC5D.
Identify IP white space around FcRH5 TCE formats
FcRH5 remains under-represented in patent filings relative to GPRC5D — use PatSnap Eureka to map the gaps.
Combination & Next-Generation Strategies in RRMM
Retrieved results signal four distinct combination and next-generation approaches designed to address antigen escape and extend clinical benefit in heavily pre-treated RRMM.
Anti-BCMA CAR-T + GPRC5D×CD3 Bispecific
The most advanced combination strategy in this dataset. A 2025 WO patent filing by Janssen Biotech explicitly claims this combination for RRMM patients who have received at least one prior line of therapy, as well as transplant-ineligible newly diagnosed patients. Endpoints include MRD-negativity at 10⁻⁵ and IMWG-defined sCR — signaling near-term or ongoing clinical investigation.
BCMA/GPRC5D/CD3 Trispecific Antibody
The Janssen trispecific patent (2023) describes a single molecule simultaneously engaging BCMA, GPRC5D, and CD3 — designed to intrinsically prevent dual-antigen escape without requiring combination of separate agents. This represents a next-generation format relative to current bispecifics, addressing the antigen escape mechanisms identified by the University of Calgary genomic study.
Key Takeaways for R&D and IP Teams
Janssen holds a dominant commercial IP position in this dataset across the GPRC5D×CD3 bispecific axis (talquetamab), the BCMA/GPRC5D/CD3 trispecific space, and the combination of anti-BCMA CAR-T with GPRC5D×CD3 BsAb — representing a vertically integrated IP strategy from single bispecific through trispecific and combination modalities. Competing developers entering the GPRC5D×CD3 or FcRH5×CD3 space face a well-constructed Janssen IP landscape.
Antigen escape is the central unresolved challenge in this therapeutic space. Retrieved genomic resistance data (University of Calgary, 2023) and preclinical biology data (ICR London, 2021) both confirm that single-target strategies — whether CAR-T or TCE — are vulnerable to target downregulation or biallelic deletion. This mechanistic insight provides the primary scientific justification for multi-antigen approaches (BCMA + GPRC5D, or BCMA + GPRC5D + FcRH5).
FcRH5 remains under-represented in patent filings within this dataset relative to GPRC5D, suggesting potential IP white space for FcRH5×CD3 TCE-specific claims, combination strategies involving FcRH5, or FcRH5 in multispecific formats. PatSnap Analytics can be used to map this white space systematically.
Daratumumab-refractory RRMM represents the most actionable near-term patient population for GPRC5D- and FcRH5-targeting TCEs. Retrieved preclinical data for talquetamab explicitly demonstrate preserved activity in daratumumab-refractory MM (median 6 prior lines). The PatSnap customer success library includes case studies from pharma teams navigating similar competitive IP landscapes in oncology.
Computational modeling platforms (QSP, physiologically based PK/PD) are emerging as drug development tools for TCE molecular format optimization, as evidenced by Sanofi and Takeda publications in this dataset. Access to PatSnap's open API enables integration of patent and literature signals into computational drug design pipelines.
GPRC5D & FcRH5 Bispecific T-Cell Engagers — key questions answered
GPRC5D (G protein-coupled receptor family C group 5 member D) is an orphan receptor with significantly elevated expression on myeloma plasma cells relative to normal plasma cells and other immune cells. Preclinical data from the Institute of Cancer Research, London, confirm that GPRC5D surface expression is meaningfully higher on MM cells and is maintained regardless of prior daratumumab exposure or cytogenetic risk profile, rendering it a compelling immunotherapeutic target across diverse patient subpopulations — including daratumumab-refractory cases with a median of six prior therapies.
A Chinese single-arm Phase II trial (Jiangsu Key Laboratory of Bone Marrow Stem Cells) reports an overall response rate of 91% (95% CI provided) in 33 patients with RRMM infused with anti-GPRC5D CAR-T cells at 2×10⁶ cells/kg after lymphodepletion, with a median follow-up of 5.2 months. The ICR London paper (2021) also describes preclinical activity of talquetamab in bone marrow samples from 45 RRMM patients, including daratumumab-refractory cases.
FcRH5 (Fc receptor-like 5; also encoded by FCRL5) is a cell surface marker selectively enriched on malignant plasma cells compared with other hematologic lineages and normal tissues. A Genentech-authored phase I study of DFRF4539A, an anti-FcRH5 antibody conjugated to MMAE, enrolled 39 patients with RRMM at doses of 0.3–2.4 mg/kg every 3 weeks or 0.8–1.1 mg/kg weekly. Adverse events included anemia (26%) and grade ≥3 events in 39% of patients. FcRH5-targeting TCE (cevostamab, FcRH5×CD3) is referenced in bispecific antibody review literature as showing promising early-phase results in RRMM.
A University of Calgary study (2023) identified biallelic deletions at the TNFRSF17 locus (BCMA gene), selective expansion of BCMA-negative subclones, and GPRC5D protein downregulation as tumor-intrinsic escape mechanisms. The study examined 30 patients treated with anti-BCMA and/or anti-GPRC5D CAR-T/TCE therapy using combined bulk and single-cell whole-genome sequencing, providing granular resistance mechanism data.
Janssen Biotech, Inc. / Janssen Pharmaceutica N.V. is the dominant commercial patent filer in this dataset. Retrieved patents include BCMA/CD3 and GPRC5D/CD3 bispecific antibodies for cancer therapy (Singapore, 2020), a trispecific antibody targeting BCMA, GPRC5D, and CD3 (Israel, 2023), and methods for treating multiple myeloma with CAR-T cells and bispecific antibodies (WO, 2025). Genentech is represented through the FcRH5 clinical axis.
The most advanced combination strategy in this dataset is the sequential or concurrent use of anti-BCMA CAR-T cells and talquetamab (GPRC5D×CD3). A 2025 WO patent filing by Janssen Biotech explicitly claims this combination for RRMM patients who have received at least one prior line of therapy. The Janssen trispecific patent (2023) also describes a single molecule simultaneously engaging BCMA, GPRC5D, and CD3 — designed to intrinsically prevent dual-antigen escape.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About RRMM BispecificsAccelerate Your RRMM Bispecific Research with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map the GPRC5D, FcRH5, and BCMA bispecific patent landscape — instantly.
References
- Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma — Myeloma Group, The Institute of Cancer Research, London, 2021 [Paper]
- Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial — Jiangsu Key Laboratory of Bone Marrow Stem Cells, 2023 [Paper]
- Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma — University of Calgary, 2023 [Paper]
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma — Genentech, Inc., 2019 [Paper]
- Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma — Cancer Center Amsterdam, Vrije Universiteit Amsterdam, 2021 [Paper]
- Bispecific antibodies in multiple myeloma treatment: A journey in progress — Division of Hematology & Oncology, Kaohsiung Medical University, 2022 [Paper]
- BCMA/CD3 and GPRC5D/CD3 bispecific antibodies for use in cancer therapy — Janssen Biotech, Inc., Singapore, 2020 [Patent]
- Trispecific antibody targeting BCMA, GPRC5D, and CD3 — Janssen Pharmaceutica N.V., Israel, 2023 [Patent]
- Methods for treating multiple myeloma with CAR-T cells and bispecific antibodies — Janssen Biotech, Inc., WO, 2025 [Patent]
- Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma — Sanofi, 2022 [Paper]
- Leveraging a physiologically based quantitative translational modeling platform for designing bispecific T cell engagers for treatment of multiple myeloma — Takeda Pharmaceuticals International Co., 2021 [Paper]
- Combination of BCMA-directed T cell therapy and an immunomodulatory compound — Juno Therapeutics, Inc., Israel, 2022 [Patent]
- Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma — Dana-Farber Cancer Institute, Harvard Medical School, 2021 [Paper]
- Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma — Osaka University Graduate School of Medicine, 2019 [Paper]
- Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis — University Medical Center Groningen, 2020 [Paper]
- WIPO — World Intellectual Property Organization: Global patent database for GPRC5D and FcRH5 bispecific filings
- ClinicalTrials.gov — Registry of early-phase FcRH5×CD3 (cevostamab) and GPRC5D-targeting clinical studies in RRMM
- NIH — National Institutes of Health: Research programs on antigen escape mechanisms in myeloma immunotherapy
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.